Leucemias

Question 1

LMA
Favorable

Answer 1

t(8;21)(q22;q22.1)/RUNX1::RUNX1T1
inv(16)(p13.1q22) or t(16;16)(p13.1;q22)/
CBFB::MYH11
Mutated NPM1 without FLT3-ITD
bZIP in-frame mutated CEBPAk

Question 2

LMA
intermediário

Answer 2

Mutated NPM1 with FLT3-ITD
Wild-type NPM1 with FLT3-ITD (without
adverse-risk genetic lesions)
t(9;11)(p21.3;q23.3)/MLLT3::KMT2A
Cytogenetic and/or molecular
abnormalities not classified as
favorable or adverse
Adverse t(6;9)(p23.3;q34.1)/DEK:

Question 3

LMA
alto risco

Answer 3

t(6;9)(p23.3;q34.1)/DEK::NUP214
t(v;11q23.3)/KMT2A-rearranged
t(9;22)(q34.1;q11.2)/BCR::ABL1
t(8;16)(p11.2;p13.3)/KAT6A::CREBBP
inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2)/
GATA2, MECOM(EVI1)
t(3q26.2;v)/MECOM(EVI1)-rearranged
25 or del(5q); 27; 217/abn(17p)
Complex karyotype, monosomal
karyotype
Mutated ASXL1, BCOR, EZH2, RUNX1,
SF3B1, SRSF2, STAG2, U2AF1, and/or
ZRSR2
Mutated TP53a

Question 4

Mutações fundadoras
DTA

Answer 4

DNMT3a
TET2
ASXL1

Question 5

Mutações cooperativas

Answer 5

Rux1
CEBP
IDH 1 e 2
NPM1

Question 6

NMP1 positivo
Característica da IF

Answer 6

Negativo para CD34

Question 7

Mutações Sinalização

Answer 7

RAS
FLT3
PTPN11
CBL

Question 9

LMA com anormalidades genéticas definidoras > 10 %, exceto ?

Answer 9

BCR ABL. Precisa de mais de 20%

Question 10

LMA > 10% anormalidade genéticas defindoras
t(15:17)(q24.1;q21.2)

Answer 10

PML-RARA

Question 11

LMA > 10% anormalidade genéticas defindoras
t(8:21)(q22;q22.1)

Answer 11

RUNX1-RUNx1T1

Question 12

LMA inv(16)(p13.1q22) ou t(16;16)(p13.1;q22)

Answer 12

CBFB-MYH11

Question 13

LMA t(6;9)(p22.3;q34.1)

Answer 13

DEKNUP214

Question 14

t(9;22)(q34.1;q11.2)

Answer 14

BCR-ABL > 20% de blastos

Question 15

LMA t(9;11)(p21.3; q23.3)

Answer 15

MLLT3-KMT2A

Question 16

LMA com inv(3)(q21.3;q26.2)

Answer 16

GATA2, MECOM

Question 17

LPA
Características fenotípicas

Answer 17

Immunophenotypic features of APL
• CD34 and HLA-DR frequently absent
• Strong and highly homogeneous CD33 expression
• Heterogeneous expression of CD13
• Absence or very low expression of CD15, CD11a-b-c
• Expression of CD56 and CD2 (M3v)

Question 18

ATRA
efeitos colaterais

Answer 18

Hipertensão Intracraniana
Elevação de aminotransferases

Question 19

Persistencia molecular

Answer 19

Pós terceira consolidação